Objective: To evaluate the natural history of treated and untreated cervical intraepithelial neoplasia-2 (CIN2) among HIVpositive women.
INTRODUCTION
Women living with HIV have a higher risk of cervical intraepithelial neoplasia (CIN) and cervical cancer, as well as higher risk of human papillomavirus (HPV) infection, compared with HIV-negative women. [1] [2] [3] [4] [5] Currently, most women diagnosed with CIN2 or more advanced cervical disease are counseled to undergo excision of the abnormal tissue, regardless of HIV status. 6, 7 However, there is evidence that treatment by excision can affect cervical competence resulting in subsequent pregnancy complications, 8 including preterm delivery. 9, 10 Women living with HIV would then be disproportionally affected by these adverse treatment effects given the higher risk of CIN development. Advances in HIV therapies have improved the overall health of HIV-positive individuals and effectively prevented mother-to-child transmission in the United States, 11 with approximately 8500 American women with HIV giving birth annually. 11 Thus, studying the risk of CIN2 progression among HIV-positive women of reproductive age can provide more precise guidance on treatment options for women and their health care providers.
In this study, we evaluated the natural history of CIN2 among a group of women of reproductive age enrolled in the Women's Interagency HIV Study (WIHS), a longstanding observational cohort of HIV-positive and high-risk HIVnegative women. To provide additional guidance for HIVpositive women of reproductive age with CIN2, we sought to ascertain the risk of CIN2 progression, determine the time it takes for CIN2 progression to occur, and identify factors associated with CIN2 progression.
METHODS
Data for this study were obtained from the WIHS, a prospective observational cohort study in which HIV-positive and high-risk HIV-negative women were enrolled at 6 sites (Bronx and Brooklyn, NY; Chicago, IL; Los Angeles and San Francisco, CA; and Washington, DC) during 3 recruitment phases: 1994-1995, 2000-2001, and 2012-2013. 12,13 Data for the current study spanned from October 1, 1994 , to September 30, 2013 (total enrollment: 2599 HIV-positive and 912 HIV-negative women). The study design of the WIHS is detailed elsewhere. 12 Treatment is not offered through the WIHS, as the study is solely observational; however, study staff members refer participants to seek treatment and care from their providers. Written informed consent was obtained from all WIHS FIGURE 1. Flowchart of study population determination from the Women's Interagency HIV Study (WIHS). Cervical intraepithelial neoplasia-2 (CIN2) regression defined as a lower grade lesion than CIN2 on all subsequent biopsies or negative Pap tests across all follow-up visits. CIN2 progression defined as any cervical disease greater than CIN2 by histology at least 6 months after the index visit. Stable disease was defined as having CIN2 persist in any follow-up visits after the index visit. Women were excluded from the current study if high-grade cervical disease was noted before the CIN2 index visit, if follow-up did not occur in at least 2 visits after CIN2 diagnosis, and if progression was noted within 6 months of the CIN2 index visit.
participants. The local institutional review boards reviewed and approved all study-related activities at each WIHS site.
A total of 251 women with biopsy-confirmed cervical CIN2 before the age of 46 (the cutoff used to include women of reproductive age) were included. These 251 women must have had an adequate colposcopy at the time of CIN2 biopsy, where the pathologist noted the lesion was visible, to ensure an accurate biopsy. Of the 251 initially identified women, 98 were excluded because of a biopsy-confirmed diagnosis of CIN3, adenocarcinoma in situ, or invasive cervical cancer in a visit before the CIN2 diagnosis. A further 27 women were excluded who did not have at least 2 follow-up evaluations for cervical disease by Pap test or histology within 2-year post-CIN2 diagnosis. Eight women were excluded who had a CIN3 diagnosis within 6 months of CIN2 index visit and were likely misclassified at the index visit. Thus, 118 women (104 HIV-positive and 14 HIV-negative) were included in this study (Fig. 1) .
Three potential outcomes were defined: progression, regression, or stable disease. CIN2 disease regression was defined as either: (1) a lower grade lesion than CIN2 on all subsequent biopsies (CIN1 or no abnormality detected) or (2) normal Pap tests across all follow-up visits after the index visit. Disease progression was defined as any cervical disease greater than CIN2 by histology at least 6 months after the index visit-CIN3 or cervical cancer diagnosis within 6 months was considered CIN2 misclassification at the initial visit and not included in further analyses. Stable disease was defined as having CIN2 persists in any follow-up visits after the index visit.
Covariates included demographic variables, behavioral factors, reproductive and gynecologic medical history, and HIV-related health information. Demographic variables included race [white (reference), black, Hispanic, and other] and age (continuous). Behavioral factors included smoking status [never smoker (reference), current smoker, and former smoker]. A categorical number of current sexual partners were considered by gender and number (Table 1) but condensed into total partner number within the previous 6 months for regression analyses. Reproductive and gynecologic medical characteristics included treatment of CIN2 received on a date within the same 6-month WIHS visit window (yes/no), percentage of abnormal cells at colposcopy [less than 25% (reference), 25-less than 50%, 50-less than 75%, greater than 75%], and overall impression of cervix at colposcopy [normal (reference), abnormal, but no squamous intraepithelial lesions (SIL), low-grade, and high-grade neoplasia]. Current pregnancy, cervical examination adequacy (satisfactory, endocervical speculum used to visualize squamocolumnar junction, or unsatisfactory), and Pap test results [normal, ASC-US, atypical squamous cells cannot exclude high-grade SIL (HSIL) (ASC-H), low-grade SIL (LSIL), and The use of combination antiretroviral therapy (cART), 14 CD4 + T-cell count, 14 plasma HIV RNA level, number of sexual partners, 14, 15 and smoking status 14, 15 were considered time-varying covariates. CIN2 treatment was analyzed as a time-varying variable coded as follows: (1) for those treated within 6 months of the index visit, the index visit and all follow-up visits were "CIN2-treated"; (2) for those who began treatment in any follow-up visit, the visits before treatment were "untreated" and the visit on or after treatment initiation was "treated"; and (3) for those never treated, all visits were "untreated."
Chi-square test or Fisher's exact test was used to compare categorical variables, and Student t test or Wilcoxon rank-sum test was used to compare numeric variables. The Kaplan-Meier method was used to describe cumulative hazard of CIN2 progression after the index visit, stratified by CIN2 treatment. Inverse probability-weighted estimation was used to estimate the effectiveness of CIN2 treatment, 16 including the following covariates: age, race, smoking status, cART use, pregnancy, partner number, CD4 + T-cell count, and HIV plasma viral load (data not shown). Inverse probability weighting did not demonstrate differences between the CIN2-treated and CIN2-untreated groups, thus Cox-proportional hazards models, where covariates of interest can be explored rather than merely controlled for, were used. Cox-proportional hazards models with time-dependent covariates were used to estimate associations of risk factors with time to CIN2 progression. Variables significant in the univariate analysis (P , 0.05) were included in the multivariate analysis. Participants were followed to either CIN2 progression or censored events (eg, death, loss to follow-up, and reaching the most recent visit). An alpha level of 0.05 and 2-tailed tests were used to determine significance in all statistical tests. All statistical analyses were performed using SAS 9.3 (SAS Inc, Carey, NC).
A sensitivity analysis was conducted to determine whether diagnoses of "nonspecific dysplasia" by biopsy could be categorized as progression events. We reanalyzed data with "nonspecific dysplasia" as a progression event, using the Kaplan-Meier and Cox-proportional hazard models. We found cART use was significantly associated with, and protective against, the hazard of CIN2 progression in multivariate analysis (adjusted odds ratio 0.20; 95% confidence interval: 0.05 to 0.71), controlling for CIN2 treatment and CD4 + T-cell count; however, all other findings were similar to the main analysis. We thus present the more stringent analysis that excludes "nonspecific dysplasia" diagnoses as progression events.
RESULTS
Among the 2559 HIV-positive and 912 HIV-negative women in the WIHS at the time of this analysis, 104 (4.1%) HIV-positive and 14 (1.5%) HIV-negative women met our inclusion criteria (Fig. 1) . The 118 women contributed 2379 visits in total (2076 HIV-positive and 303 HIV-negative). Among these women, 53% were black, 34% were Hispanic, and 53% were current smokers at the time of the index visit (Table 1) . Women living with HIV were significantly older †P-value cannot be determined as all same-visit treatment events occurred within the CIN2-treated category.
ASC-H, atypical squamous cells, cannot exclude HSIL; ES, endocervical speculum used to visualize squamocolumnar junction; IQR, interquartile range.
than HIV-negative women (33 vs. 28 years, P , 0.001); all other examined sociodemographic characteristics and smoking status were similar between HIV-positive and HIVnegative women (Table 1) .
The likelihood of ever-receiving CIN2 treatment during the follow-up period differed by HIV status but did not reach statistical significance (57.1% HIV-negative vs. 40.4% HIVpositive, P = 0.26). Among women living with HIV, indexvisit Pap test results differed significantly between those treated vs. untreated for CIN2 (P = 0.02) ( Table 2) . Seven women with a normal Pap test were examined by colposcopy. Although it is not the routine practice to perform a colposcopy after a normal Pap test, 5 of these 7 women had an indication for colposcopy through an LSIL or ASC-US finding within the previous 6 months at WIHS. One additional woman was referred to colposcopy because it was routine for first visit in the core WIHS, and for one woman, the colposcopy was for visible cervical lesions. Most CIN2-treated HIV-positive women had LSIL on Pap test at the index visit (Table 2) . However, colposcopy findings, age, CD4 + T-cell count, plasma HIV RNA level, and cART use at the index visit were similar between CIN2-untreated and CIN2-treated HIVpositive women (Table 2 ). CIN2-treated and CIN2-untreated HIV-positive women were also followed for similar periods after the initial diagnosis (median 10.0 years vs. 10.1 years).
Overall, 12.7% of women in the study progressed within the median 10-year follow-up. CIN2 progression was seen in 11.5% of HIV-positive women and 21.4% of HIV-negative women ( Table 1) Kaplan-Meier analysis was used to explore the time to CIN2 progression in HIV-positive women treated vs. untreated for CIN2. There was no significant difference in the number of years to CIN2 progression (3.9 vs. 3.0, P = 0.34) ( Table 2) , but the cumulative hazard of CIN2 progression was significantly different between women treated vs. untreated for CIN2 (23.5% vs. 7.2% P = 0.04) (Fig. 2) . Cumulative hazards of CIN2 progression in those CIN2-treated vs. CIN2-untreated at 2 years were 10.0% vs. 3.4%, by 5 years were 13.2 vs. 7.2%, and at 8 years were 23.5% vs. 7.2%. However, the Kaplan-Meier analysis does not adjust for other cofactors of interest.
There was no effect of CIN2 treatment on cervical disease progression on multivariate analysis (Table 3) . Similarly, inverse probability weighting confirmed the lack of treatment effect on CIN2 progression in HIV-positive women (HR 0.95, P = 0.88).
Cox-proportional hazards models were used to investigate factors associated with CIN2 progression (Table 3 ). An increase of 100 CD4 + T cells was associated with a 33% decrease in CIN2 progression (adjusted hazard ratio 0.67; 95% confidence interval: 0.47 to 0.88), but CIN2 treatment and cART use were not significantly associated with CIN2 progression in these models adjusted for CD4 count (Table 3) .
Overall, CIN2 regression was the most common result during follow-up, occurring among 73/118 (61.9%) women, with 60.6% of HIV-positive and 71.4% of HIV-negative women exhibiting cervical disease regression (Table 1) . Thirty HIV-positive and HIV-negative women demonstrated stable CIN2 diagnosis, where CIN2 persisted in a followup visit.
DISCUSSION
Within the long-term, multisite observational WIHS cohort, we found low rates of CIN2 progression over a median 10-year follow-up period in both HIV-positive and HIV-negative women, regardless of whether CIN2 treatment was received. The strongest predictor of CIN2 progression among HIV-positive women in our study related to HIV immunologic status, with higher CD4 + T-cell counts over time, showed a protective effect against CIN2 progression. In addition, a sensitivity analysis that included "nonspecific dysplasia in biopsy" diagnoses as progression events found that the hazard of CIN2 progression decreased with sustained cART use. cART use and well-maintained CD4 + T-cell counts have previously been associated with regression of cervical abnormalities among women living with HIV. 14, [16] [17] [18] [19] Although cigarette smoking has been shown to associate with the development of cervical cancer, 20 this variable was not included in our multivariate model because it did not meet the prespecified significance level in univariate analysis. We may not have identified this important modifiable variable as a risk factor for CIN2 progression in our study because of a small sample size.
We identified high rates of CIN2 regression, similar to what is reported in the literature among the general population. 21, 22 Regression of CIN2+ in women living with HIV has been previously reported at 24% over 12 months and 46% over a median of 17 months. 17 In our study, 60.6% of HIVpositive women with CIN2 showed disease regression over a median 10-year follow-up, with an additional 27.9% demonstrating stable disease. However, it should be noted that per the LAST guidelines, the recommended nomenclature now uses a two-tier system [CIN1 (low-grade squamous intraepithelial lesion) and CIN2 + 3 (high-grade SIL)] that was not in place during most data collection for the current study. 23 Because of the small numbers of HIV-negative women diagnosed at CIN2 in this study, we were unable to compare disease progression and regression rates by HIV status. We note that women living with HIV had lower rates of CIN2 treatment compared with HIV-negative women, although this was a nonsignificant 17% difference between groups. Given the small proportion of HIV-negative women in the current study, further research is needed to ensure that engagement, retention, and access to care related to HIV status are not contributing to discrepancies in cervical disease treatment in larger populations.
Our study benefits from a strict definition of CIN2, in an attempt to minimize disease misclassification given the noted interobserver variability in the pathology assessment of CIN2 or CIN3. 6 The sensitivity analysis with a broader definition of cervical disease progression (inclusion of "nonspecific dysplasia" in cervical biopsy as a progression event) had results that were similar to the current analysis, except that cART use became significantly associated with a reduced risk of CIN2 progression. This reinforces the conclusion that progression is a less common event for women receiving antiretroviral therapy with well-controlled HIV.
The current study also benefits from a long follow-up period; women were followed for a median of 10 years after the initial CIN2 diagnosis. This extended period of follow-up is critical in characterizing the natural history of cervical neoplasia, given the relative slow progression typically associated with this disease. However, the current analysis is limited by the lack of concurrent HPV typing, which is now typically used to guide CIN2/CIN3 treatment decisions. In addition, staining for p16INK4a, a biomarker associated with high-risk HPV oncogenic activity, 24 was not feasible because cervical biopsies were not banked. Future research should focus on biomarkers to distinguish women at high risk of progression vs. regression among women classified as highgrade SIL under the LAST guidelines. 23 A large proportion of women reported no CIN2 treatment in the current study despite the recommendations for treatment as standard-of-care. The WIHS does not document reasons for lack of treatment, whether they were provider selection bias, insurance and/or financial barriers, a woman's personal choice to defer treatment, or underreporting of CIN2 treatment by study participants. Furthermore, data capture on treatment may have been incomplete because treatment is not offered through WIHS. Thus, details are obtained through medical record abstraction only. CIN2 treatment was not randomized in this study, thus confounding by indication may play a role in the finding of nonassociation between CIN2 treatment and disease progression. Pap test results may have influenced CIN2 treatment decisions for women in the analysis because Pap results differed significantly between those treated or untreated.
CONCLUSIONS
In summary, the decision to use surgical treatment for management of cervical tissue abnormalities in HIV-positive women of reproductive age needs to be balanced against considerations of future childbearing because CIN treatment may be associated with adverse reproductive outcomes. [8] [9] [10] Our findings of substantial regression and limited progression of CIN2 among HIV-positive women of reproductive age with viral suppression challenges the current paradigm of immediate cervical resection; however, further research is warranted to identify the subset of women at risk of progression. Future research should incorporate concurrent HPV testing with or without measurement of biomarkers such as E6/E7 messenger RNA, p16 staining, or related immune factors to differentiate women at highest risk of progression vs. those who are unlikely to progress with conservative management in the era of effective antiretroviral therapy.
